National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018

Национальный фонд сердца Австралии и Кардиологическое общество Австралии и Новой Зеландии: рекомендации по профилактике, выявлению и лечению сердечной недостаточности в Австралии, 2018 г.
Tom G. Briffa, Maree Branagan, John James Atherton, Andrea L Driscoll, Ingrid Hopper, Walter P. Abhayaratna, Liza Thomas, Andrew Paul Sindone, Carmine G. De Pasquale, Peter Simon Macdonald, Peter M. Kistler, James Wong, Ralph G. Audehm, Phillip J. Newton, J O'Loughlin, Cia Connell, Joan O'Loughlin
2018-08-01

ACE inhibitorsSGLT2 inhibitorsheart failure diagnosisheart failure preventionleft ventricular systolic dysfunction
Tabled 1RecommendationGRADE strength of recommendationQuality of evidencePrevention of heart failure—non-pharmacologicalSmoking cessation is recommended to decrease the risk of cardiovascular events and decrease the risk of developing heart failure.StrongFORLowAvoiding excess alcohol is recommended, to decrease the risk of developing heart failure.StrongFORVery lowWeight reduction is recommended in patients who are overweight or obese, to decrease the risk of developing heart failure.StrongFORLowRegular physical activity is recommended to decrease the risk of cardiovascular events and decrease the risk of developing heart failure.StrongFORLowPrevention of heart failure—pharmacologicalBlood pressure (BP) lowering and lipid lowering according to published guidelines are recommended, to decrease the risk of cardiovascular events and decrease the risk of developing heart failure.StrongFORHighAngiotensin converting enzyme (ACE) inhibitors should be considered in patients with cardiovascular disease to decrease the risk of cardiovascular events and decrease the risk of developing heart failure.StrongFORModerateSodium-glucose cotransporter 2 (SGLT2) inhibitors are recommended in patients with type 2 diabetes mellitus associated with cardiovascular disease and insufficient glycaemic control despite metformin, to decrease the risk of cardiovascular events and decrease the risk of hospitalisation for heart failure.StrongFORHighACE inhibitors are recommended in patients with left ventricular (LV) systolic dysfunction to decrease the risk of developing heart failure.StrongFORHighBeta blockers should be considered in patients with LV systolic dysfunction to decrease the risk of developing heart failure.StrongFORLowDiagnosisA 12-lead electrocardiogram (ECG) is recommended in patients with either a suspected diagnosis or new diagnosis of heart failure, to assess cardiac rhythm, QRS duration, and the presence of underlying conditions such as myocardial ischaemia or LV hypertrophy.StrongFORLowA chest X-ray is recommended in patients with either a suspected diagnosis or new diagnosis of heart failure, to detect signs of pulmonary congestion and to identify alternative cardiac or non-cardiac causes for the patient’s symptoms.StrongFORVery lowPlasma B-type natriuretic peptide (BNP) or N-terminal proBNP (NT proBNP) levels are recommended for diagnosis in patients with suspected heart failure, when the diagnosis is uncertain.StrongFORHighA transthoracic echocardiogram is recommended in patients with suspected heart failure, to improve diagnostic accuracy, and in patients with a new diagnosis of heart failure, to assess cardiac structure and function (including the measurement of LV ejection fraction [LVEF]), assist in classification and therefore guide management.StrongFORLowInvasive coronary angiography should be considered in patients with heart failure associated with refractory angina, resuscitated cardiac arrest, sustained ventricular arrhythmias, or with evidence of ischaemic heart disease on other investigations, or an intermediate-to-high pretest probability for coronary artery disease, to determine the need for coronary revascularisation.StrongFORLowEither computed tomography (CT) coronary angiography or cardiac magnetic resonance imaging (CMR) with late gadolinium enhancement (LGE) may be considered in patients with heart failure who have a low-to-intermediate pretest probability of coronary artery disease, to distinguish ischaemic and non-ischaemic causes of ventricular dysfunction.WeakFORLowNon-invasive functional testing—stress echocardiography, single-photon emission CT scan (SPECT), positron emission tomography (PET) and CMR with LGE—may be considered in patients with heart failure and established coronary artery disease, for the assessment of myocardial ischaemia and viability to determine the need for coronary revascularisation.WeakFORVery lowCMR with LGE should be considered in patients with heart failure associated with increased LV wall thickness that remains unexplained following clinical evaluation, including a 12-lead ECG and echocardiogram to identify inflammatory and infiltrative cardiomyopathies.StrongFORLowEither PET or bone scintigraphy may be considered in patients with heart failure associated with increased LV wall thickness that remains unexplained following clinical evaluation, including a 12-lead ECG and echocardiogram to identify infiltrative cardiomyopathies.WeakFORLowBNP and NT proBNP levels may be considered in patients with an established diagnosis of heart failure for prognostic stratification.WeakFORHighGenetic testing may be considered in patients with dilated cardiomyopathy (DCM) associated with conduction disease, for prognostic stratification and to guide management regarding the use of implantable cardioverter defibrillators.WeakFORLowTransthoracic echocardiography should be considered in patients with heart failure with reduced ejection fraction (HFrEF) 3–6 months after the start of optimal medical therapy, or if there has been a change in clinical status, to assess the appropriateness for other treatments, including device therapy (implantable cardioverter defibrillator [ICD] or cardiac resynchronisation therapy [CRT], or both).WeakFORLowAcute heart failureInvestigation and management of precipitating factors is recommended in all patients presenting with acute heart failure. Acute coronary syndrome (ACS), hypertensive crisis, arrhythmia, mechanical catastrophe (e.g., ruptured interventricular septum, mitral papillary muscle or LV free wall, or acute valvular regurgitation), and pulmonary embolism should be confirmed or excluded, and managed immediately.StrongFORLowMonitoring of peripheral arterial oxygen saturation is recommended in patients with acute heart failure.StrongFORVery lowOxygen therapy is recommended in patients with acute heart failure associated with oxygen saturation levels below 94%.StrongFORVery lowNon-invasive ventilation should be considered in patients with acute heart failure associated with pulmonary congestion who remain hypoxaemic and tachypnoeic despite oxygen therapy, to improve symptoms and reduce the requirement for intubation.StrongFORHighIntravenous loop diuretics are recommended in patients with acute heart failure associated with congestion, to improve symptoms of fluid overload.StrongFORLowIntravenous vasodilators may be considered in patients with acute heart failure if the systolic blood pressure is more than 90 mm Hg, to relieve symptoms of congestion.WeakFORLowIntravenous inotropic therapy may be considered in patients with acute heart failure associated with symptoms or signs of peripheral hypoperfusion (usually accompanied by a systolic BP <90 mm Hg) and congestion refractory to other treatment, to improve symptoms and end-organ function.WeakFORVery lowIntravenous inotropic therapy should be avoided in patients without symptoms or signs of peripheral hypoperfusion and congestion refractory to other treatment.StrongAGAINSTLowPharmacological management of chronic heart failureACE inhibitorsAn ACE inhibitor is recommended in all patients with HFrEF associated with a moderate or severe reduction in LVEF (LVEF less than or equal to 40%) unless contraindicated or not tolerated to decrease mortality and decrease hospitalisation.StrongFORHighACE inhibitorsAn ACE inhibitor may be considered in patients with HFrEF associated with a mild reduction in LVEF (LVEF 41–49%) unless contraindicated or not tolerated to decrease mortality and decrease hospitalisation.WeakFORLowBeta blockersA beta blockera is recommended in all patients with HFrEF associated with a moderate or severe reduction in LVEF (LVEF less than or equal to 40%) unless contraindicated or not tolerated, and once stabilised with no or minimal clinical congestion on physical examination to decrease mortality and decrease hospitalisation.aSpecifically, bisoprolol, carvedilol, metoprolol (controlled release or extended release) or nebivololStrongFORHighBeta blockersA beta blockera may be considered in patients with HFrEF associated with a mild reduction in LVEF (LVEF 41–49%) unless contraindicated or not tolerated, and once stabilised with no or minimal clinical congestion on physical examination to decrease mortality and decrease hospitalisation.aSpecifically, bisoprolol, carvedilol, metoprolol (controlled release or extended release) or nebivololWeakFORLowMineralocorticoid receptor antagonists (MRAs) An MRA is recommended in all patients with HFrEF associated with a moderate or severe reduction in LVEF (LVEF less than or equal to 40%) unless contraindicated or not tolerated, to decrease mortality and decrease hospitalisation for heart failure.StrongFORHighMineralocorticoid receptor antagonists (MRAs)An MRA may be considered in patients with HFrEF associated with a mild reduction in LVEF (LVEF 41–49%) unless contraindicated or not tolerated, to decrease mortality and decrease hospitalisation for heart failure.WeakFORLowDiureticsA diuretic should be considered in patients with heart failure and clinical symptoms, or signs of congestion, to improve symptoms and manage congestion.StrongFORVery lowAngiotensin receptor blockers (ARBs)An is recommended in patients with HFrEF associated with a moderate or severe reduction in LVEF (LVEF less than or equal to 40%) if an ACE inhibitor is contraindicated or not tolerated, to decrease the of cardiovascular mortality and hospitalisation for heart may be in patients with HFrEF associated with a mild reduction in LVEF (LVEF 41–49%) if an ACE inhibitor is contraindicated or not tolerated, to decrease the of cardiovascular mortality and hospitalisation for heart receptor inhibitor is recommended as a for an ACE inhibitor a or an in patients with HFrEF associated with an LVEF of less than or equal to despite tolerated or of an ACE inhibitor and a beta with or without an to decrease mortality and decrease use of ACE inhibitors and are contraindicated and should not be of of an increased risk of should be considered in patients with HFrEF associated with an LVEF of less than or equal to and a of and despite tolerated or of an ACE inhibitor and a beta with or without an to decrease the of cardiovascular mortality and hospitalisation for heart may be considered in patients with HFrEF if an ACE inhibitor and are contraindicated or not tolerated to decrease may be considered in patients of with HFrEF despite tolerated or of an ACE inhibitor and a beta with or without an to decrease mortality and hospitalisation for heart may be considered in patients with HFrEF associated with and moderate to severe symptoms despite tolerated or of an ACE inhibitor to decrease hospitalisation for heart may be considered in patients with HFrEF despite tolerated or of an ACE inhibitor and a beta with or without an to decrease mortality and cardiovascular of to improve to a heart failure disease management is recommended in patients with heart failure associated with to decrease mortality and to a heart failure after is patients should be with a or is recommended in patients with HFrEF who have not tolerated of ACE beta blockers or to decrease patients and the of heart failure is recommended in patients with heart failure, to decrease hospitalisation and should after be to of and the of to moderate is recommended in patients with chronic heart failure, in with reduced to improve physical and of and to decrease and resynchronisation is recommended in patients with HFrEF associated with rhythm, an LVEF of less than or equal to and a QRS of or more despite optimal medical therapy, to decrease mortality and hospitalisation for heart failure and improve should be considered in patients with HFrEF associated with rhythm, an LVEF of less than or equal to and a QRS of despite optimal medical therapy, to decrease mortality and hospitalisation for heart failure, and improve may be considered in patients with HFrEF associated with an LVEF of less than or equal to and a QRS of or more despite optimal medical therapy to decrease and and improve symptoms, is accompanied by to should be considered in patients with HFrEF associated with an LV ejection fraction of less than or equal to accompanied by to decrease hospitalisation for heart should be considered in patients who have ventricular who symptoms of heart failure with an LVEF of less than to decrease hospitalisation for heart is contraindicated in patients with QRS of less than of of and cardioverter should be considered as a in patients following resuscitated cardiac arrest, sustained ventricular in the presence of and ventricular associated with and an LVEF of less than to decrease should be considered as a in patients following myocardial associated with an LVEF of less than or equal to to decrease should be considered as a in patients with HFrEF associated with ischaemic heart disease and an LVEF of less than or equal to to decrease may be considered as a in patients with HFrEF associated with dilated cardiomyopathy and an LVEF of less than or equal to to decrease pulmonary arterial pressure may be considered in patients who have been for heart failure associated with a reduced or LV ejection fraction with moderate functional heart failure symptoms, despite optimal to decrease hospitalisation for heart failure, are in to and of pressure management and artery should be considered in patients with HFrEF associated with ischaemic heart disease and an LVEF of less than or equal to if have coronary artery disease, to improve symptoms (e.g., of and heart failure and decrease and or the of should be considered in patients with moderate to severe mitral in with heart failure and ischaemic heart disease to improve or may be considered in patients with severe mitral dilated cardiomyopathy with heart failure who remain despite medical and cardiac device therapy to improve or may be considered in patients with moderate to severe functional mitral in with heart failure who remain despite medical and cardiac device therapy, in who are risk to improve is recommended in patients with severe or severe and heart failure in the of or to improve symptoms and decrease should be considered in patients with severe and heart failure to mortality risk or considered for and who are for following assessment by a heart to improve symptoms and decrease to a for of ventricular assist device should be considered in patients with severe heart failure despite medical and therapy, and who not to decrease of a as a to should be considered in patients for heart who or who to acute mechanical for heart assessment should be considered in patients with heart failure associated with symptoms who have all alternative and who not have to decrease and should be avoided in patients with of the risk of to guide the need for is recommended in patients with therapy for a ventricular of should be considered in patients with heart failure associated with and a ventricular for or should be considered in patients with HFrEF associated with an LVEF of less than or equal to who with to decrease mortality and hospitalisation for heart are not recommended in patients with heart failure to the risk that to of heart is not recommended in patients with HFrEF and of an increased and cardiovascular should not be for the of in patients with heart failure of an increased risk of patients with HFrEF associated with symptoms despite therapy, should be if the is or with saturation should be to improve symptoms and of of heart failure with ejection a has been antagonists inhibitors or or beta blockers and should be in patients with heart failure associated with a or ejection to decrease the risk of to should be considered in patients with heart failure to symptoms, improve of and decrease of should be considered in the heart converting acute coronary receptor receptor B-type natriuretic blood coronary artery cardiac magnetic resonance cardiac resynchronisation computed dilated of and heart failure with reduced ejection implantable cardioverter late gadolinium left LV ejection receptor mitral positron emission cotransporter single-photon emission CT ventricular assist in a new converting acute coronary receptor receptor B-type natriuretic blood coronary artery cardiac magnetic resonance cardiac resynchronisation computed dilated of and heart failure with reduced ejection implantable cardioverter late gadolinium left LV ejection receptor mitral positron emission cotransporter single-photon emission CT ventricular assist clinical guidelines for the management of heart failure to regarding the clinical of patients with heart failure in on are to the of the of of and for the and of in of and the of and for the and management of chronic heart failure in late the the of developing the and to the with the as the for regarding the and for the on the in of the with the clinical to be in the according to on the established to the following and a and by on the of and in other of the with and the clinical on to the of the guidelines the established of with in the of heart failure in of the to and the of the the for and the guidelines and and to of the by the clinical to the of for according to to and to not in and by the and the clinical the and for are in an in in the of and in evidence and by the and for the guidelines on the evidence the the evidence and for the the other than for the on the of the of in by the to of the by the clinical and the of the and and for in of considered a of the or of the to with in the the and the and of the of the and to all of and months and of managed by the or of the of and be in an and a of the for the of guidelines be on the to of published and by other clinical and clinical of and of and to the strength of a for or an is by the of and and of or in and and is by in and of the and by the and the with and by the of more than of all of the a of the evidence the or other factors are in the and other there is a evidence or the of on clinical considered to be are in the of the may be in are to to such as the for and should with with to and including the in or of and who are or failure with of and a for the of risk of developing heart failure for and is and the heart failure risk and of heart failure and more than in of and in are with heart failure. of heart failure in are of heart failure and systolic ventricular dysfunction in the of heart failure in a and the of heart failure has been that there or more with heart failure, of the and of heart failure in the a the of cardiovascular risk factors and the of heart disease in the of heart failure in is than in failure a may or heart and less the heart of have increased to of the in the and of of the may guidelines for the and management of are in the guidelines for the and management of acute and heart disease with heart failure have more and mortality than who are not and are more to heart failure than of of in heart failure is not associated with an in heart failure has been to be either or in the of heart a of in of heart and of patients with heart failure to the of diagnostic and more therapy the in heart failure the reduction in heart failure, associated with reduced left ventricular ejection fraction may be to for ischaemic heart disease and for acute coronary in that there is an of patients with heart failure associated with ejection fraction to the that more than of heart failure in and of heart failure with ejection there heart failure and cardiomyopathy as the or of all in of for heart failure and cardiomyopathy as the hospitalisation for than than in all increased with with for and or more than in the of and the and of patients with heart failure in the of and as HFrEF heart failure in and the the for heart failure on the has acute or chronic heart failure. acute heart failure, in are and for patients to with heart in in following acute heart the Acute for chronic heart failure to and to and of patients with heart failure in and following a diagnosis of heart failure in a to have in patients with HFrEF and in and of heart failure with ejection of heart failure with ejection fraction in a a of with patients a mortality of with a mortality in HFrEF prognostic of heart failure with left ventricular ejection a in of patients with heart failure with or reduced left ventricular ejection an confirmed in a patients mortality for HFrEF and for as as of in patients with the in mortality with the of in patients with heart failure of left ventricular ejection fraction in of patients with heart failure with or reduced left ventricular ejection an failure is a clinical syndrome with symptoms and signs that on when is to an of cardiac structure or function that the of the heart to with blood pressure or blood to the of the is the disease and to heart failure, as clinical diagnosis is a clinical and the of the syndrome the of cardiac dysfunction on symptoms and clinical syndrome of heart failure has are of heart failure is is of are of heart and and a and of a of heart symptoms of heart failure are and signs of heart failure be to cardiac dysfunction and heart and reduced end-organ congestion cardiac in pressure and peripheral pulmonary and and signs of heart and signs of heart (usually with heart of when heart of to the and the and and the as in a new of to the and the and and the as when of heart failure and on physical the heart failure syndrome symptoms on levels of physical activity and An is the fluid that for and functional classification of heart functional classification of heart of physical of physical symptoms of physical symptoms on physical activity or in a new of cardiac structure or the end-organ of the heart failure the underlying is a cardiac ventricular myocardial systolic or dysfunction of cardiac the to the and conduction to the syndrome of heart failure. the of the heart to with blood the with An to with blood without increased pressure to reduced ventricular or or in symptoms and signs of congestion of the and the of the heart to if the heart is and as a a reduction in blood and therefore in cardiac to the that is insufficient for the of the in symptoms and in heart failure is with heart failure may be according to LVEF as classification of heart failure is on the as should be either echocardiography (usually with the of or or may be a more of left ventricular (LV) the and for cardiac by echocardiography in An the of and the of and that measurement is not in clinical the use of LVEF as the of LV to heart failure following the of ventricular that is of for the LVEF is as a ejection systolic that the is a of cardiac ejection and therefore of systolic is to the classification of heart failure HFrEF systolic heart is as the clinical symptoms with or without signs of heart failure and a LVEF of less than if the LVEF is reduced (LVEF are (e.g., signs of heart failure or evidence of dysfunction failure diagnostic failure diagnostic signs of heart LVEF LVEF reduced (LVEF (e.g., signs of heart dysfunction with pressure by or echocardiography or signs of heart LVEF evidence heart disease left with pressure by of the or NT proBNP) or B-type natriuretic heart failure with ejection heart failure with reduced ejection left left ejection LVEF reduced (LVEF (e.g., signs of heart dysfunction with pressure by or echocardiography or in a new B-type natriuretic heart failure with ejection heart failure with reduced ejection left left ejection LVEF to identify patients with HFrEF in the has to with a of a for that are may be to by clinical evidence and or heart has more to the of cardiac is by clinical symptoms and are the of remains an and is as all of the following symptoms with or without signs of heart of evidence of either heart disease or dysfunction without an alternative (e.g., valvular heart heart to LV or left LV LV wall thickness or LV of more than or more than ventricular is a associated and of in of more than is a of function LV of and ventricular ventricular and ventricular may in increased dysfunction to of pressure by of the pulmonary pressure of more than or equal to mm or LV pressure of more than mm of the of less than of less than mitral of more than of more than of more than for the of left ventricular function by an the of and the of for natriuretic and diagnostic for is and in to factors natriuretic peptide levels of diagnostic proBNP failure failure B-type natriuretic for is and in to factors natriuretic peptide levels of in a new B-type natriuretic as symptoms of heart failure on evidence of pressure be on testing may therefore be considered in patients the clinical of despite not the testing an of and imaging the for myocardial ischaemia as an alternative of the of diagnosis is with measurement of of pressure either if mm or with echocardiography when all of the following or and or following and for the of left ventricular function by an the of and the of of testing in the for heart failure with ejection a a to HFrEF and for not a for that HFrEF and have clinical and there is no syndrome or for in LVEF measurement by echocardiography is the of is to a new and with diagnostic is an clinical of the of patients with heart failure associated with a in may of the failure with ejection fraction in and of the ejection fraction beta blockers for heart failure with and ejection an of and receptor antagonists (MRAs) of ejection fraction on and of in patients with heart failure with ejection to patients with heart failure associated with an LVEF of less than therefore following a clinical diagnosis of heart failure, an LVEF of or more be considered and an LVEF of less than be considered HFrEF to management HFrEF the has to more than with should be considered and HFrEF the is not to have in left ventricular dysfunction to reduced LVEF with no or clinical evidence of heart failure. in a risk for the of heart failure. or heart failure to the and diagnosis of heart failure in a of symptoms may be to or to that patients have not heart failure heart failure to patients with heart failure for a of as a of that patients have heart failure Acute heart failure and a to the acute or of symptoms of heart failure to of acute heart failure are Acute pulmonary medical by the acute or of pulmonary as the clinical of left heart failure with of fluid the pulmonary and in the of failure and and without medical with a is by the acute of reduced cardiac and blood pressure <90 mm Hg) in the of heart failure mm Hg) to the end-organ is failure and a acute myocardial functional (e.g., acute myocardial or acute or a cardiac (e.g., acute valvular is in the as an in the chronic heart failure has a more Acute heart failure of acute heart failure in is an acute in a with for are and disease factors and of in with management of the heart failure. more with a of of with symptoms and signs of congestion chronic to acute heart of heart failure to or failure of the causes are ventricular or the of heart failure is heart pressure heart is a and is to is a of chronic in valvular heart disease, chronic disease, chronic failure, pulmonary not a disease heart failure is an with a is the of in cardiac and chronic including valvular heart disease, chronic pulmonary disease disease and pulmonary arterial diagnosis and management of pulmonary arterial is the of with HFrEF have reduced LV systolic function to a of underlying causes systolic function reduce cardiac has end-organ of (e.g., and inflammatory and myocardial cardiac of heart of heart are not or or (e.g., or and and (e.g., (e.g., (e.g., or (e.g., or diabetes (e.g., or dilated left ventricular ventricular and and valvular dysfunction and or fluid (e.g., ventricular or of to the and the and and the as are not in a new of to the and the and and the as factors in the of HFrEF of a with acute in increased and and of reduced cardiac and heart failure for the heart failure have of is less as a heart in and of the left is that is a of heart failure in and the is more in patients with a of as as and for and coronary to and reduced in of myocardial and myocardial myocardial for heart failure with ejection myocardial
1
A 12-lead ECG is recommended for suspected or newly diagnosed heart failure to assess rhythm, QRS duration, myocardial ischaemia, and left-ventricular hypertrophy.
2
ACE inhibitors are recommended for patients with cardiovascular disease or left-ventricular systolic dysfunction, while beta blockers should be considered for left-ventricular systolic dysfunction.
3
Blood-pressure and lipid lowering according to established guidelines is strongly recommended to reduce cardiovascular events and incident heart failure, supported by high-quality evidence.
4
SGLT2 inhibitors are recommended for patients with type 2 diabetes, cardiovascular disease, and inadequate glycaemic control despite metformin, reducing cardiovascular events and heart-failure hospitalization.
5
The 2018 Australian guidelines strongly recommend smoking cessation, avoiding excess alcohol, weight reduction, and regular physical activity to prevent heart failure and cardiovascular events.

heart failure in Australian patients and populations at risk

prevention, detection, and management strategies for heart failure, including lifestyle interventions, pharmacotherapy, and diagnostic assessment

Publication Details
Publication Date
2018-08-01
Journal
Publisher
ISSN
Cited by
437
Access Type
Author Information
Authors
Tom G. Briffa
Maree Branagan
John James Atherton
Andrea L Driscoll
Ingrid Hopper
Walter P. Abhayaratna
Liza Thomas
Andrew Paul Sindone
Carmine G. De Pasquale
Peter Simon Macdonald
Peter M. Kistler
James Wong
Ralph G. Audehm
Phillip J. Newton
J O'Loughlin
Cia Connell
Joan O'Loughlin
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%